8-K

                            Microsoft Word 11.0.5604;
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported)  March 4, 2005
                                                 ---------------


                           Molecular Diagnostics, Inc.
- -------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

        Delaware                        0-935                   36-4296006
- -------------------------------------------------------------------------------
(State or other jurisdiction         (Commission              (IRS Employer
    of incorporation)                 File Number)          Identification No.)


414 North Orleans Street, Suite 502, Chicago, Illinois                60610
- ------------------------------------------------------------------------------
      (Address of principal executive offices)                     (Zip Code)


Registrant's telephone number, including area code (312) 222-9550
                                                   --------------

                                 Not Applicable
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)


      Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

[ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))



                                TABLE OF CONTENTS

                                    FORM 8-K



Item                                                                        Page

Item 5.02         Departure of Directors or Principal Officers; Election
                  of Directors; Appointment of Principal Officers             1

Item 9.01         Financial Statements and Exhibits                           1

Signature                                                                     1



Item 5.02 Departure of Directors or Principal Officers; Election of
          Directors; Appointment of Principal Officers

      (b) On March 4, 2005, Peter P. Gombrich informed the Board of Directors
that has was resigning as Chairman of the Board and as a director of the
Company, effective immediately. A copy of the Company's press release is
attached as Exhibit 99.1 and is incorporated herein by reference. Mr. Gombrich
also informed the Board of Directors, by letter dated March 16, 2005, that he
was resigning from the Company effective immediately; Mr. Gombrich had been
employed as an Executive Vice President of the Company.


Item 9.01         Financial Statements and Exhibits

      (c)         Exhibits

      99.1        Press Release dated March 8, 2005

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                        Molecular Diagnostics, Inc.



Dated: March 29, 2005                   By:/s/ Denis M. O'Donnell, M.D.
                                           ----------------------------------
                                        Denis M. O'Donnell, M.D.
                                        President and Chief Executive Officer

EX-99.1

[LETTERHEAD OF MOLECULAR DIAGNOSTICS]                              PRESS RELEASE
                                                           For immediate release


CONTACTS:

Molecular Diagnostics, Inc.
- ---------------------------
Denis M. O'Donnell, M.D.
Chief Executive Officer
(312) 222-9550

                      MOLECULAR DIAGNOSTICS, INC. ANNOUCES
                              DIRECTOR RESIGNATION

CHICAGO, IL, March 8, 2005 - Molecular Diagnostics, Inc. (OTCBB: MCDG.OB)
announced today that Peter Gombrich, Chairman of the Board of Directors,
resigned as Chairman of the Board and as a director of the company, effective
today.

About Molecular Diagnostics, Inc.
Molecular Diagnostics develops cost-effective cancer screening systems, which
can be utilized in a laboratory or at the point-of-care, to assist in the early
detection of cervical, gastrointestinal, and other cancers. The InPath(TM)
System is being developed to provide medical practitioners with a highly
accurate, low-cost, cervical cancer screening system that can be integrated into
existing medical models or at the point-of-care.

More information is available at: www.Molecular-Dx.com

Certain statements in this release are forward-looking. These statements are
based on Molecular Diagnostics' current expectations and involve many risks and
uncertainties, such as the company's inability to obtain sufficient financing,
the possibility that clinical trials will not substantiate Molecular
Diagnostics' expectations with respect to the InPath(TM) System, and other
factors set forth in reports and documents filed by Molecular Diagnostics with
the Securities and Exchange Commission. Actual results may differ materially
from Molecular Diagnostic's current expectations depending upon a number of
factors affecting the Company's business. These factors include, among others,
risks and uncertainties detailed in the Company's periodic public filings with
the Securities and Exchange Commission, including but not limited to the
Company's Annual Report on Form 10-K for the year ended December 31, 2003 and
its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2004, June
30, 2004 and September 30, 2004 (as amended). Except as expressly required by
law, Molecular Diagnostics undertakes no obligation to publicly update or revise
any forward-looking statements contained herein.